Antihypertensive Use and the Risk of Cataract in Patients with Hypertension: A Nationwide Case-control Study

References

• WHO. Action plan for the prevention of avoidable blindness and visual impairment, 2009-2013. World Health Organization. https://www.who.int/blindness/ACTION_PLAN_WHA62-1-English.pdf. Accessed January 6, 2021
   Google Scholar
• Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol. 2012;96(5):614–618. doi:10.1136/bjophthalmol-2011-300539.
   PubMed Web of Science ®Google Scholar
• Gupta VB, Rajagopala M, Ravishankar B. Etiopathogenesis of cataract: an appraisal. Indian J Ophthalmol. 2014;62(2):103–110. doi:10.4103/0301-4738.121141.
   PubMed Web of Science ®Google Scholar
• Leske MC, Wu SY, Hennis A, Connell AM, Hyman L, Schachat A. Diabetes, hypertension, and central obesity as cataract risk factors in a black population. The barbados eye study. Ophthalmology. 1999 Jan;106(1):35–41. doi:10.1016/s0161-6420(99)90003-9.
   PubMed Web of Science ®Google Scholar
• Galeone C, Petracci E, Pelucchi C, Zucchetto A, La Vecchia C, Tavani A. Metabolic syndrome, its components and risk of age-related cataract extraction: a case-control study in Italy. Ann Epidemiol. 2010 May;20(5):380–384. doi:10.1016/j.annepidem.2010.01.009.
   PubMedGoogle Scholar
• Tavani A, Negri E, La Vecchia C. Selected diseases and risk of cataract in women. A case-control study from northern Italy. Ann Epidemiol. 1995 May;5(3):234–238. doi:10.1016/1047-2797(94)00111-6.
   PubMedGoogle Scholar
• Yu X, Lyu D, Dong X, He J, Yao K. Hypertension and risk of cataract: a meta-analysis. PLoS One. 2014;9(12):e114012. doi:10.1371/journal.pone.0114012.
   PubMed Web of Science ®Google Scholar
• Park SJ, Lee JH, Kang SW, Hyon JY, Park KH. Cataract and cataract surgery: nationwide prevalence and clinical determinants. J Korean Med Sci. 2016 Jun;31(6):963–971. doi:10.3346/jkms.2016.31.6.963.
   PubMed Web of Science ®Google Scholar
• Gu Q, Paulose-Ram R, Dillon C, Burt V. Antihypertensive medication use among US adults with hypertension. Circulation. 2006;113(2):213–221. doi:10.1161/CIRCULATIONAHA.105.542290.
   PubMedGoogle Scholar
• Kanthan GL, Wang JJ, Rochtchina E, Mitchell P. Use of antihypertensive medications and topical beta-blockers and the long-term incidence of cataract and cataract surgery. Br J Ophthalmol. 2009 Sep;93(9):1210–1214. doi:10.1136/bjo.2008.153379.
   PubMedGoogle Scholar
• Becker C, Jick SS, Meier CR. ACE inhibitor use and risk of cataract: a case-control analysis. Article. Br J Ophthalmol. 2019;103(11):1561–1565. doi:10.1136/bjophthalmol-2018-312980.
   PubMedGoogle Scholar
• Cumming RG, Mitchell P. Medications and cataract. The blue mountains eye study. Ophthalmology. 1998 Sep;105(9):1751–1758. doi:10.1016/s0161-6420(98)99049-2.
   PubMedGoogle Scholar
• Choudhary R, Bodakhe SH. Olmesartan, an angiotensin II receptor blocker inhibits the progression of cataract formation in cadmium chloride induced hypertensive albino rats. Life Sci. 2016 December 15;167:105–112. doi:10.1016/j.lfs.2016.10.012.
   PubMed Web of Science ®Google Scholar
• Hightower KR, Reddy VN. Calcium content and distribution in human cataract. Exp Eye Res. 1982 March 01;34(3):413–421. doi:10.1016/0014-4835(82)90087-2.
   PubMed Web of Science ®Google Scholar
• Hightower KR, Reddy VN. Ca++-induced cataract. Invest Ophthalmol Vis Sci. Feb 1982;22(2):263–267.
   PubMed Web of Science ®Google Scholar
• Seong SC, Kim -Y-Y, Park SK, et al. Cohort profile: the national health insurance service-national health screening cohort (NHIS-HEALS) in Korea. BMJ Open. 2017;7(9):e016640.doi:10.1136/bmjopen-2017-016640.
   PubMed Web of Science ®Google Scholar
• Desai RJ, Glynn RJ, Wang S, Gagne JJ. Performance of disease risk score matching in nested case-control studies: a simulation study. Am J Epidemiol. 2016 May 15;183(10):949–957. doi:10.1093/aje/kwv269.
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005 Nov;43(11):1130–1139. doi:10.1097/01.mlr.0000182534.19832.83.
   PubMed Web of Science ®Google Scholar
• Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38(6):1228–1234. doi:10.1080/03610910902859574.
   Web of Science ®Google Scholar
• McGlothlin AE, Lewis RJ. Minimal clinically important difference: defining what really matters to patients. Review. JAMA J Am Med Assoc. 2014;312(13):1342–1343. doi:10.1001/jama.2014.13128.
   PubMed Web of Science ®Google Scholar
• Hays RD, Woolley JM. The concept of clinically meaningful difference in health-related quality-of-life research. Pharmacoeconomics. 2000;18(5):419–423. doi:10.2165/00019053-200018050-00001.
   PubMed Web of Science ®Google Scholar
• Alvarez LJ, Candia OA, Polikoff LA. Beta-adrenergic stimulation of Na(+)-K(+)-2Cl(-) cotransport activity in the rabbit lens. Exp Eye Res. 2003 Jan;76(1):61–70. doi:10.1016/s0014-4835(02)00254-3.
   PubMedGoogle Scholar
• Chopra M, Scott N, McMurray J, et al. Captopril: a free radical scavenger. Br J Clin Pharmacol. 1989;27(3):396–399.doi:10.1111/j.1365-2125.1989.tb05384.x.
   PubMedGoogle Scholar
• Bhuyan KC, Bhuyan DK, Santos O, Podos SM. Antioxidant and anticataractogenic effects of topical captopril in diquat-induced cataract in rabbits. Free Radic Biol Med. 1992;12(4):251–261. doi:10.1016/0891-5849(92)90112-t.
   PubMedGoogle Scholar
• Klein BE, Klein R, Lee KE, Danforth LG. Drug use and five-year incidence of age-related cataracts: the Beaver Dam Eye Study. Ophthalmology. 2001 Sep;108(9):1670–1674. doi:10.1016/s0161-64200100656-x.
   PubMed Web of Science ®Google Scholar
• Mylona I, Dermenoudi M, Ziakas N, Tsinopoulos I. Hypertension is the prominent risk factor in cataract patients. Medicina (Kaunas). 2019;55(8):430. doi:10.3390/medicina55080430.
   PubMedGoogle Scholar
• Xu X, Ritz B, Coleman A, et al. Hypertension, antihypertensive medications use and risk of age-related macular degeneration in California Teachers Cohort. J Hum Hypertens. Oct 8, 2019;34:568–576. doi:10.1038/s41371-019-0269-9.
   PubMedGoogle Scholar
• Khan SA, Choudhary R, Singh A, Bodakhe SH. Hypertension potentiates cataractogenesis in rat eye through modulation of oxidative stress and electrolyte homeostasis. J Curr Ophthalmol. 2016 September 01;28(3):123–130. doi:10.1016/j.joco.2016.05.001.
   PubMed Web of Science ®Google Scholar
• Sabanayagam C, Wang JJ, Mitchell P, et al. Metabolic syndrome components and age-related cataract: the Singapore Malay eye study. Invest Ophthalmol Vis Sci. 2011;52(5):2397–2404.doi:10.1167/iovs.10-6373.
   PubMed Web of Science ®Google Scholar
• Bezin J, Mansiaux Y, Noize P, Salvo F, Begaud B, Pariente A. Use of lipid-lowering drugs and the risk of cataract: a population-based nested case-control study. Clin Pharmacol Ther. 2019 Feb;105(2):458–465. doi:10.1002/cpt.1176.
   PubMedGoogle Scholar
• Smeeth L, Hubbard R, Fletcher AE. Cataract and the use of statins: a case-control study. QJM. 2003 May;96(5):337–343. doi:10.1093/qjmed/hcg064.
   PubMedGoogle Scholar
• Smeeth L, Boulis M, Hubbard R, Fletcher AE. A population based case-control study of cataract and inhaled corticosteroids. Br J Ophthalmol. 2003;87(10):1247–1251. doi:10.1136/bjo.87.10.1247.
   PubMed Web of Science ®Google Scholar
• Casula M, Soranna D, Corrao G, Merlino L, Catapano AL, Tragni E. Statin use and risk of cataract: a nested case-control study within a healthcare database. Atherosclerosis. Aug 2016;251:153–158. doi:10.1016/j.atherosclerosis.2016.06.020.
   PubMedGoogle Scholar
• Erie JC, Pueringer MR, Brue SM, Chamberlain AM, Hodge DO. Statin use and incident cataract surgery: a case-control study. Ophthalmic Epidemiol. 2016;23(1):40–45. doi:10.3109/09286586.2015.1077258.
   PubMed Web of Science ®Google Scholar